[go: up one dir, main page]

NZ601588A - Methods for treating breast cancer - Google Patents

Methods for treating breast cancer

Info

Publication number
NZ601588A
NZ601588A NZ601588A NZ60158811A NZ601588A NZ 601588 A NZ601588 A NZ 601588A NZ 601588 A NZ601588 A NZ 601588A NZ 60158811 A NZ60158811 A NZ 60158811A NZ 601588 A NZ601588 A NZ 601588A
Authority
NZ
New Zealand
Prior art keywords
breast cancer
methods
treating breast
treating
hpg
Prior art date
Application number
NZ601588A
Inventor
Jean-Francois Floch
Leila Houhou
Francoise Cailler
Dominique Joubert
Frederic Hollande
Original Assignee
Servier Lab
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Servier Lab
Publication of NZ601588A publication Critical patent/NZ601588A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Discloses the use of a human progastrin monoclonal antibody (hPG) for use in a method for preventing or treating breast cancer.
NZ601588A 2010-01-08 2011-01-07 Methods for treating breast cancer NZ601588A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29361210P 2010-01-08 2010-01-08
PCT/EP2011/000048 WO2011083090A2 (en) 2010-01-08 2011-01-07 Methods for treating breast cancer

Publications (1)

Publication Number Publication Date
NZ601588A true NZ601588A (en) 2014-07-25

Family

ID=43607948

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ601588A NZ601588A (en) 2010-01-08 2011-01-07 Methods for treating breast cancer
NZ601591A NZ601591A (en) 2010-01-08 2011-01-07 Methods for treating pancreatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601591A NZ601591A (en) 2010-01-08 2011-01-07 Methods for treating pancreatic cancer

Country Status (15)

Country Link
US (2) US9487582B2 (en)
EP (2) EP2542583B8 (en)
JP (2) JP6134141B2 (en)
KR (2) KR101438362B1 (en)
CN (2) CN102933603B (en)
AU (2) AU2011204653B2 (en)
BR (2) BR112012016820A2 (en)
CA (2) CA2786479C (en)
EA (2) EA025329B1 (en)
ES (2) ES2657245T3 (en)
NZ (2) NZ601588A (en)
PL (2) PL2542583T3 (en)
SG (2) SG182334A1 (en)
WO (2) WO2011083090A2 (en)
ZA (2) ZA201205003B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
AU2011284908B2 (en) * 2010-07-26 2015-05-21 Centre National De La Recherche Scientifique (Cnrs) Methods and compositions for liver cancer therapy
CA2996205A1 (en) 2015-09-20 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
KR102477179B1 (en) 2015-12-31 2022-12-13 프로가스트린 에 캔서스 에스.에이 알.엘. Compositions and methods for detecting and treating gastric cancer
ES2987412T3 (en) 2015-12-31 2024-11-14 Ecs Progastrin Sa Compositions and procedures for assessing the risk of cancer occurrence
BR112018013272A2 (en) 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L compositions and methods for detecting and treating esophageal cancer
ES3015244T3 (en) * 2015-12-31 2025-04-30 Ecs Progastrin Sa Compositions and methods for detecting and treating ovarian cancer
ES2932262T3 (en) * 2017-01-06 2023-01-17 Lemonex Inc Composition for the prevention or treatment of metastatic ovarian cancer, endometrial cancer or breast cancer
ES2926532T3 (en) * 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Compositions and methods for treating lung cancer
US11614448B2 (en) 2017-03-30 2023-03-28 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
CN111050789A (en) * 2017-06-15 2020-04-21 癌症进展有限公司 Compositions and methods for inducing humoral and cellular immunity against tumors and cancers
US11267881B2 (en) 2017-09-14 2022-03-08 Charles ROSSER Compositions and methods for treatment of diseases involving CXCL1 function
JP7104153B2 (en) * 2017-12-05 2022-07-20 プロガストリン、エ、カンセル、エス、アー エル、エル Combination therapy of anti-progastrin antibody and immunotherapy to treat cancer
WO2019110845A1 (en) 2017-12-08 2019-06-13 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
US20200400675A1 (en) 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
KR102808710B1 (en) 2018-03-13 2025-05-15 페인스 테라퓨틱스 인코포레이티드 Anti-Folate Receptor 1 Antibodies and Uses Thereof
CN108864255B (en) * 2018-06-21 2022-01-04 天津医科大学肿瘤医院 Breast cancer stem cell specific binding polypeptide and application thereof in preparation of medicine for treating breast cancer
US11292832B2 (en) 2019-01-28 2022-04-05 Charles J. Rosser Compositions and methods for treatment of diseases involving CXCL1 function

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
PT981369E (en) * 1997-05-12 2005-03-31 Aphton Corp IMMUNOGENIC COMPOSITIONS FOR THE CCK-B / GASTRIN RECEPTOR AND METHODS FOR THE TREATMENT OF TUMORS
JP2003523404A (en) 2000-02-25 2003-08-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Membrane estrogen receptor for treatment in breast cancer
FR2846426B1 (en) 2002-10-28 2004-12-10 Bio Merieux METHOD FOR ASSAYING NGF FOR IN VITRO DIAGNOSIS OF BREAST CANCER AND USE IN THERAPY
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
CN101460196A (en) * 2006-05-22 2009-06-17 国立医学与健康研究所 Progastrin inhibitors in the treatment of colon cancer
US20100158894A1 (en) 2006-09-15 2010-06-24 Tokai University Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2009042618A1 (en) 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
CN102791735B (en) * 2009-10-16 2016-05-18 瑟维尔实验室 Anti-progastrin monoclonal antibody and use thereof

Also Published As

Publication number Publication date
AU2011204653B2 (en) 2014-04-10
EP2542583A2 (en) 2013-01-09
EP2542583B1 (en) 2017-10-25
EP2542583B8 (en) 2017-12-13
WO2011083090A3 (en) 2011-10-06
BR112012016820A2 (en) 2023-11-28
CA2786479C (en) 2016-03-15
ZA201205003B (en) 2013-09-25
SG182331A1 (en) 2012-08-30
CN102892784A (en) 2013-01-23
CN102933603A (en) 2013-02-13
SG182334A1 (en) 2012-08-30
WO2011083091A3 (en) 2011-09-09
CA2786435C (en) 2017-01-17
CN102933603B (en) 2016-01-20
WO2011083091A8 (en) 2012-08-09
EP2542584A2 (en) 2013-01-09
EP2542584B1 (en) 2017-10-25
WO2011083091A2 (en) 2011-07-14
BR112012016742A2 (en) 2018-05-15
PL2542584T3 (en) 2018-04-30
CA2786435A1 (en) 2011-07-14
WO2011083090A2 (en) 2011-07-14
AU2011204654B2 (en) 2014-04-10
US8900588B2 (en) 2014-12-02
AU2011204654A1 (en) 2012-07-26
EA201200999A1 (en) 2013-02-28
EA025329B1 (en) 2016-12-30
KR20120135401A (en) 2012-12-13
US20110171213A1 (en) 2011-07-14
US9487582B2 (en) 2016-11-08
CA2786479A1 (en) 2011-07-14
CN102892784B (en) 2016-06-22
JP2013516439A (en) 2013-05-13
JP5572718B2 (en) 2014-08-13
US20110177062A1 (en) 2011-07-21
PL2542583T3 (en) 2018-04-30
ZA201205004B (en) 2013-09-25
ES2657246T3 (en) 2018-03-02
EP2542584B8 (en) 2017-12-13
JP2013516438A (en) 2013-05-13
KR101438362B1 (en) 2014-09-05
JP6134141B2 (en) 2017-05-24
NZ601591A (en) 2015-01-30
ES2657245T3 (en) 2018-03-02
KR101468397B1 (en) 2014-12-04
EA201200998A1 (en) 2013-02-28
KR20130028050A (en) 2013-03-18
AU2011204653A1 (en) 2012-07-26
EA023722B1 (en) 2016-07-29

Similar Documents

Publication Publication Date Title
NZ601588A (en) Methods for treating breast cancer
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
NZ628314A (en) Cd47 antibodies and methods of use thereof
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
MX2011010955A (en) Adjuvant cancer therapy.
NZ601584A (en) Methods for treating colorectal cancer
SG194701A1 (en) Anti-cd40 antibodies and methods of use
AU2012335543A8 (en) HER3 antibodies and uses thereof
NZ631197A (en) Anti sez6 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
PT2766040T (en) Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
PH12013501942A1 (en) Antibody-drug conjugates
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
MX2015005810A (en) Anti-notch3 antibodies and antibody-drug conjugates.
MX342240B (en) Anti-fgfr4 antibodies and methods of use.
UA106890C2 (en) LibreOfficeantibody to CDCP1
MX370573B (en) Gla monotherapy for use in cancer treatment.
MX347320B (en) Agr2 blocking antibody and use thereof.
MX2014002053A (en) Anti-mcsp antibodies.
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
NZ611785A (en) Anti-notch1 antibodies
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PT2550296T (en) Monoclonal antibodies for treatment of cancer
MX2014001766A (en) Neuregulin antibodies and uses thereof.
GB201109238D0 (en) Antibodies

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20130509

Owner name: LES LABORATOIRES SERVIER, FR

Effective date: 20130509

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20130509

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2016 BY AJ PARK

Effective date: 20141125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2017 BY AJ PARK

Effective date: 20151208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2018 BY AJ PARK

Effective date: 20161221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2019 BY AJ PARK

Effective date: 20171227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2020 BY ACUMASS

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2021 BY ACUMASS

Effective date: 20191219

LAPS Patent lapsed